Healthcare / Diagnostics & ResearchNasdaqGM
$19.83
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $28.3M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$601M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-5.1%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
+47.4%
FCF CAGR
—
FCF margin
8.2%
FCF / Net income
-1.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $344.2M · net income $-24.2M · FCF $28.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $344.2M | $344.2M | $332.1M | $219.8M | $137.0M | $94.1M | $62.6M | $51.9M | $22.8M |
| Net Income | $-24.2M | $-24.2M | $18.2M | $-57.5M | $-67.1M | $-31.3M | $-10.3M | $5.3M | $-6.4M |
| EBITDA | $-2.0M | $-2.0M | $24.7M | $-55.6M | $-62.3M | $-36.7M | $-6.1M | — | — |
| EPS | -0.83 | -0.83 | 0.62 | -2.14 | -2.58 | -1.24 | -0.54 | -0.21 | -5.33 |
| Gross Margin | — | — | — | — | — | — | 84.5% | 85.9% | 76.8% |
| Operating Margin | -12.4% | -12.4% | 2.6% | -30.9% | -53.2% | -42.6% | -10.4% | 14.1% | -16.8% |
| Net Margin | -7.0% | -7.0% | 5.5% | -26.1% | -49.0% | -33.3% | -16.4% | 10.2% | -27.9% |
| Balance Sheet | |||||||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.00 | — | — | 0.00 | 0.23 | -0.43 |
| Cash Flow | |||||||||
| Free Cash Flow | $28.3M | $28.3M | $36.5M | $-19.2M | $-47.3M | $-22.5M | $5.1M | $6.1M | $-12.6M |
| Returns | |||||||||
| ROE | -5.1% | -5.1% | 4.0% | -14.7% | -16.8% | -7.6% | -2.5% | 6.2% | 11.3% |
| Growth & Yield | |||||||||
| Revenue Growth | 3.7% | 3.7% | 51.1% | 60.4% | 45.7% | 50.2% | 20.8% | 127.6% | — |
| EPS Growth | -233.9% | -233.9% | 129.0% | 17.1% | -108.1% | -129.6% | -157.1% | 96.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.